Betaxolol
Title: Betaxolol
CAS Registry Number: 63659-18-7
CAS Name: 1-[4-[2-(Cyclopropylmethoxy)ethyl]-phenoxy]-3-[(1-methylethyl)amino]-2-propanol
Additional Names: (±)-1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol
Molecular Formula: C18H29NO3
Molecular Weight: 307.43
Percent Composition: C 70.32%, H 9.51%, N 4.56%, O 15.61%
Literature References: Cardioselective b1-adrenergic blocker. Prepn: P. M. J. Manoury et al., DE 2649605; eidem, US 4252984 (1977, 1981 both to Synthelabo). Blood concn and pharmacodynamic effects: S. J. Warrington et al., Br. J. Clin. Pharmacol. 10, 449 (1980). Pharmacokinetics: G. Bianchetti et al., Arzneim.-Forsch. 30, 1912 (1980). Cardiovascular effects in normal volunteers: P. J. Cadigan et al., Br. J. Clin. Pharmacol. 9, 569 (1980). Efficacy and pharmacokinetics: K. Balnave et al., ibid. 11, 171 (1981). Use in treatment of glaucoma: A. R. Berrospi, H. M. Leibowitz, Arch. Ophthalmol. 100, 943 (1982). Antihypertensive effect: M. Pathe et al., Therapie 37, 75 (1982). Book: Betaxolol and Other b1-Adrenoceptor Antagonists, P. L. Morselli et al., Eds. (Raven Press, New York, 1983) 385 pp.
Properties: Crystals from petr ether, mp 70-72°.
Melting point: mp 70-72°
 
Derivative Type: Hydrochloride
CAS Registry Number: 63659-19-8
Manufacturers' Codes: SLD-212; SL-75.212
Trademarks: Betoptic (Alcon); Betoptima (Alcon); Kerlone (Synthelabo)
Molecular Formula: C18H29NO3.HCl
Molecular Weight: 343.89
Percent Composition: C 62.87%, H 8.79%, N 4.07%, O 13.96%, Cl 10.31%
Properties: Crystals from acetone, mp 116°. LD50 in mice (mg/kg): 944 orally; 37 i.v. (Manoury).
Melting point: mp 116°
Toxicity data: LD50 in mice (mg/kg): 944 orally; 37 i.v. (Manoury)
 
Therap-Cat: Antihypertensive; antiglaucoma.
Keywords: ?Adrenergic Blocker; Antiglaucoma; Antihypertensive; Aryloxypropanolamine Derivatives.

Others monographs:
Calcium Iodostearate4-Nitrobenzoyl ChlorideValpromide3-Pyrroline
FluocinonideOsmiumBoron TrifluorideSulfathiourea
OpipramolBenzyl AcetateTioconazoleTetradifon
m-AminophenolTEMPOTitanium DichlorideTebufenpyrad
©2016 DrugLead US FDA&EMEA